TMX-2172

Overview

TMX-2172 is a selective bivalent cereblon-recruiting PROTAC -based dual CDK2 and CDK5 degrader with IC 50 values of 6.5 nM and 6.8 nM, respectively. TMX-2172 shows selectivity for CDK2 and CDK5 over other cell cycle CDKs ( CDK1 , CDK4 , and CDK6 ) and transcriptional CDKs ( CDK7 and CDK9 ). TMX-2172 inhibits CDK2/CDK5 enzymatic activity, induces their proteasomal degradation, reduces ASCL1 protein levels and half-life, induces cancer cell death, and exerts antiproliferative effects. TMX-2172 can be used for the research of ovarian cancer and small cell lung cancer . (Pink: CDK2 and CDK5 Target protein ligand; Blue: Cereblon ligand ( HY-41547 ); Black: linker ( HY-W008352 )).

Application

Products | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-155218
• CAS No.: 2488892-09-5
• Molecular Formula: C41H45BrFN9O11S
• Molecular Weight: 970.82
• Purity: 99.38%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (2.58 mM); Clear solution
• Availability: In-stock

Source

Original product source